Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

201495 citationsJournal Articlegreen Open Access

Authors

Paul Dorian · St. Michael's Hospital

Thitima Kongnakorn

Hemant Phatak · Bristol-Myers Squibb (United States)

Dale Rublee · Pfizer (United States)

Andreas Kuznik · Pfizer (United States)

Tereza Lanitis · EVRAZ (United Kingdom)

Liu Lz

U Iloeje ·

Abstract

Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Antiplatelet Therapy and Cardiovascular Diseases Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 35, Issue 28, pp. 1897-1906

DOI: 10.1093/eurheartj/ehu006

Field-Weighted Citation Impact: 11.05